Robertson S E, Traverso H P, Drucker J A, Rovira E Z, Fabre-Teste B, Sow A, N'Diaye M, Sy M T, Diouf F
Division of Immunization, Centers for Disease Control, Atlanta, Georgia.
Lancet. 1988 Apr 23;1(8591):897-9. doi: 10.1016/s0140-6736(88)91711-4.
The 1986-87 outbreak of paralytic poliomyelitis in Senegal, with 676 reported cases, provided an opportunity to evaluate the efficacy of an enhanced-potency inactivated poliovirus vaccine (N-IPV) in the Kolda region, where this vaccine has been used since 1980. 89 cases, confirmed to have poliomyelitis with residual paralysis, were enrolled in a case-control study, up to 5 matched controls being obtained for each case. The clinical efficacy for one dose of N-IPV was 36% (95% confidence interval 0%, 67%) and for two doses was 89% (95% CI 62%, 97%).
1986 - 1987年塞内加尔爆发麻痹性脊髓灰质炎，报告病例达676例，这为评估强化效力的灭活脊髓灰质炎病毒疫苗（N - IPV）在科尔达地区的效果提供了契机，自1980年起该地区就开始使用这种疫苗。89例确诊为脊髓灰质炎且有残留麻痹症状的病例被纳入一项病例对照研究，每个病例最多匹配5名对照。一剂N - IPV的临床效力为36%（95%置信区间0%，67%），两剂的效力为89%（95%置信区间62%，97%）。
